Diffuse Large B-Cell Lymphoma (DLBCL) Cell Models for Research

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, accounting for approximately 30-40% of all NHL cases globally. According to the World Health Organization (WHO) GLOBOCAN 2020 data, there were over 544,000 new cases of non-Hodgkin lymphoma worldwide, with DLBCL representing a significant proportion. The age-standardized incidence rate is about 5-6 per 100,000 person-years in Western countries, with a median age at diagnosis of 65 years. The 5-year overall survival for DLBCL varies by stage and risk factors: localized disease (Stage I-II) has a 5-year survival of approximately 70-80%, while advanced-stage disease (Stage III-IV) drops to 50-60% (NCI SEER data). Key risk factors include immunosuppression (HIV, organ transplantation), autoimmune diseases (e.g., Sjögren syndrome), and certain infections (Epstein-Barr virus, Helicobacter pylori). Despite advances with R-CHOP immunochemotherapy, about 30-40% of patients relapse or become refractory, highlighting the urgent need for novel targeted therapies and predictive biomarkers.

DLBCL is an ideal model for mechanistic studies due to its well-characterized molecular heterogeneity, classified into cell-of-origin (COO) subtypes: germinal center B-cell (GCB), activated B-cell (ABC), and primary mediastinal B-cell lymphoma (PMBL). These subtypes exhibit distinct genetic landscapes and clinical outcomes, making DLBCL a paradigm for precision oncology. Public datasets such as TCGA (The Cancer Genome Atlas) and COSMIC provide extensive genomic, transcriptomic, and epigenetic data, enabling researchers to identify driver mutations and dysregulated pathways. Open questions include the role of tumor microenvironment, mechanisms of therapy resistance, and the functional impact of co-occurring mutations. Gene-edited cell models, such as CRISPR knockouts and knock-ins, allow controlled perturbation of specific genes to dissect their contribution to lymphomagenesis and drug response, accelerating target validation and drug discovery.

DLBCL pathogenesis involves multiple oncogenic pathways that drive uncontrolled proliferation, survival, and immune evasion. Key pathways include:

• • B-cell receptor (BCR) signaling: Chronic active BCR signaling is a hallmark of ABC-DLBCL, leading to NF-κB activation. Mutations in CD79A/B and MYD88 (e.g., MYD88 L265P) are common.
• • NF-κB pathway: Constitutive activation of NF-κB promotes survival and proliferation. Mutations in CARD11, TNFAIP3 (A20), and MYD88 are frequent.
• • PI3K/AKT/mTOR pathway: Deregulation enhances cell growth and survival. PTEN loss and PIK3CA mutations are observed.
• • Apoptosis regulation: BCL2 overexpression (due to t(14;18) translocation) and TP53 mutations impair apoptosis.
• • Epigenetic regulation: Mutations in histone modifiers (EZH2, CREBBP, EP300) and chromatin remodelers (KMT2D) alter gene expression.
• • JAK/STAT pathway: Mutations in SOCS1 and STAT3 contribute to immune evasion and proliferation.

These pathways are interconnected, and their dysregulation often co-occurs, driving tumor heterogeneity.

Data from TCGA (Cell 2018, 173:917-929) and COSMIC v95.

The molecular networks deregulated in DLBCL include:

• • BCR/NF-κB axis: Chronic BCR signaling activates BTK, PLCγ2, and PKCβ, leading to CARD11-BCL10-MALT1 (CBM) complex formation and NF-κB nuclear translocation. Key nodes: BTK, MYD88, IRAK1/4, IKKβ.
• • PI3K/AKT/mTOR: PI3K activation (via BCR or receptor tyrosine kinases) generates PIP3, recruiting AKT. PTEN loss or PIK3CA mutations amplify this. Downstream effectors include mTORC1, FOXO, and GSK3β.
• • Apoptotic machinery: BCL2 overexpression sequesters pro-apoptotic proteins (BAX, BAK). TP53 mutations impair DNA damage response. Survivin and XIAP are also upregulated.
• • Epigenetic remodeling: EZH2 (H3K27 methyltransferase) and CREBBP (histone acetyltransferase) mutations alter chromatin states, affecting gene expression programs.
• • JAK/STAT: Cytokine signaling (IL-4, IL-6) activates JAKs, phosphorylating STAT3/5, promoting survival and immune evasion.
• • MAPK/ERK: RAS/RAF/MEK/ERK cascade is activated via BCR or growth factor receptors, contributing to proliferation.

These networks provide multiple therapeutic targets, and gene-edited models are essential for dissecting their crosstalk and resistance mechanisms.

These cell lines are widely used for functional studies. Organoid models, though less established for DLBCL, are emerging as 3D culture systems that better recapitulate tumor microenvironment and drug responses. They can be derived from patient samples and genetically modified using CRISPR, offering a more physiologically relevant platform for drug testing.

Animal models are critical for in vivo validation. Common models include:

• • Patient-derived xenografts (PDX): Immunodeficient mice (NSG) engrafted with patient DLBCL cells. They preserve tumor heterogeneity and are used for drug efficacy testing.
• • Genetically engineered mouse models (GEMM): Conditional knock-in of MYD88 L265P or BCL2 overexpression in B cells (e.g., Eμ-Myc; BCL2) recapitulate DLBCL features.
• • Induced models: Use of Cre-lox systems to delete tumor suppressors (e.g., TP53) or activate oncogenes (e.g., EZH2) in germinal center B cells.
• • Syngeneic models: Mouse lymphoma cell lines (e.g., A20) implanted in immunocompetent mice to study immune interactions.

These models are essential for studying tumor microenvironment, metastasis, and immunotherapy response.

CRISPR-based gene editing enables the generation of isogenic cell lines with precise genetic modifications, such as knockouts (KO), knock-ins (KI), point mutations, and reporter tags. These models are invaluable for studying gene function in a controlled background. Examples include:

• • TP53 knockout in OCI-LY1 to study p53 loss effects on drug sensitivity.
• • MYD88 L265P knock-in in a GCB cell line to convert it to an ABC-like phenotype.
• • CD79B knockout to abrogate BCR signaling and assess downstream effects.
• • EZH2 Y641N knock-in to study epigenetic changes.

Commercially available, sequence-verified gene-edited cell lines (from commercial sources) accelerate research by providing validated models with minimal off-target effects. These models are used for target validation, drug screening, and mechanistic studies, reducing the time and cost of in-house editing.

Gene-edited cells enable systematic functional annotation of genetic alterations. For example:

• • CRISPR knockout of MYD88 in ABC-DLBCL cells (e.g., TMD8) reduces NF-κB activity and cell viability, confirming its oncogenic dependency.
• • Knock-in of EZH2 Y641N in GCB cells increases H3K27me3 levels and alters gene expression, validating its role in lymphomagenesis.
• • Loss-of-function screens using CRISPR libraries (e.g., DepMap) identify essential genes in DLBCL, such as BCL2, MCL1, and IRF4.

These models help prioritize therapeutic targets and understand synthetic lethal interactions.

Isogenic pairs (wild-type vs. mutant) are powerful for drug screening. For instance:

• • TP53-null DLBCL cells show increased resistance to DNA-damaging agents (e.g., doxorubicin), mimicking clinical resistance.
• • MYD88 L265P knock-in cells are sensitive to BTK inhibitors (e.g., ibrutinib) but can develop resistance via secondary mutations; gene-edited models can be used to study resistance mechanisms.
• • CRISPR-mediated knockout of BCL2 sensitizes cells to BCL2 inhibitors (e.g., venetoclax), validating the target.

These models are essential for identifying biomarkers of response and developing combination therapies.

Gene-edited cells facilitate biomarker discovery through:

• • CRISPR synthetic lethality screens: For example, knocking out TP53 in DLBCL cells and screening for genes whose loss is lethal only in TP53-null background, identifying potential therapeutic targets.
• • Reporter cell lines: GFP-tagged NF-κB or BCR reporters allow real-time monitoring of pathway activity, useful for high-content screening.
• • Secretome analysis: Knockout of specific genes can reveal changes in cytokine secretion, identifying potential biomarkers for prognosis or response.

These applications accelerate precision medicine by linking genetic alterations to functional phenotypes.